| 中文名称: | ADH-503 | ||||
|---|---|---|---|---|---|
| 英文名称: | ADH-503 | ||||
| 别名: | (Z)-Leukadherin-1 choline | ||||
| CAS No: | 2055362-74-6 | 分子式: | C27H28N2O5S2 | 分子量: | 524.65 |
| CAS No: | 2055362-74-6 | ||||
| 分子式: | C27H28N2O5S2 | ||||
| 分子量: | 524.65 | ||||
基本信息
|
产品编号： |
A11593 |
||||
|
产品名称： |
ADH-503 |
||||
|
CAS: |
2055362-74-6 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
|
||||
|
分子式： |
溶于液体 |
-80℃ |
两年 |
||
|
分子量 |
524.65 |
-20℃ |
一个月 |
||
|
化学名： |
(Z)-Leukadherin-1 choline |
||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
100mg/mL(190.23mM) |
|||
|
Ethanol |
4mg/mL(7.6mM) |
||||
|
Water |
Insoluble |
||||
|
体内(现配现用): |
1.请依序添加每种溶剂：10% DMSO→90% (20% SBE-β-CD in saline) Solubility:≥2.14mg/mL(4.08mM);Clear solution |
||||
|
此⽅案可获得≥2.14mg/mL(4.08mM，饱和度未知)的澄清溶液。以1mL⼯作液为例，取100μL21.400002mg/mL的澄清DMSO储备液加到900μL20%的SBE-β-CD⽣理盐⽔⽔溶液中，混合均匀。 |
|||||
|
2.请依序添加每种溶剂：10% DMSO→90% corn oil Solubility:≥2.14mg/mL(4.08mM);Clear solution |
|||||
|
此⽅案可获得≥2.14mg/mL(4.08mM，饱和度未知)的澄清溶液，此⽅案不适⽤于实验周期在半个⽉以上的实验。以1mL⼯作液为例，取100μL21.400002mg/mL的澄清DMSO储备液加到900μL⽟⽶油中，混合均匀。 |
|||||
|
3.请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80→45% saline，Solubility:2.08mg/mL(3.96mM);Suspended solution; Need ultrasonic |
|||||
|
此⽅案可获得2.08mg/mL(3.96mM)的均匀悬浊液，悬浊液可⽤于⼝服和腹腔注射。以1mL⼯作液为例，取100μL20.8mg/mL的澄清DMSO储备液加到400μLPEG300中，混合均匀；向上述体系中加⼊50μLTween-80，混合均匀；然后继续加⼊450μL⽣理盐⽔定容⾄1mL。 |
|||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
1.9024mL |
9.5119mL |
19.0237mL |
|
5mM |
0.3805mL |
1.9024mL |
3.8047mL |
|
10mM |
0.1902mL |
0.9512mL |
1.9024mL |
|
50mM |
0.0380mL |
0.1902mL |
0.3805mL |
生物活性
|
产品描述 |
一种具有口服活性的，变构的CD11b激动剂。 |
|
|
靶点 |
CD11b() |
|
|
体外研究 |
ADH-503 ((Z)-Leukadherin-1 choline; 4μM; 8 days) reduces the numbers of total tumor-infiltrating CD11b+ cells and subsets of CD11b+ monocytes, granulocytes, eosinophils, and macrophages |
|
|
体内研究 |
ADH-503 ((Z)-Leukadherin-1 choline; oral gavage; 30, 60, or 120mg/kg; twice a day for 60 days) delayes tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival ADH-503 (oral gavage; 30, 100mg/kg; twice a day; on days 1 and 5) has the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594ng/mL and AUC0-t in the plasma of 6950 and 13962ng.h/mL at 30 and 100mg/kg dosing, respectively |
|
|
Animal Model: |
KPC mice [p48-CRE/Lox-stop-Lox(LSL)-KrasG12D/p53flox/flox] |
|
|
Dosage: |
30, 60, or 120mg/kg |
|
|
Administration: |
Oral gavage; 60 days |
|
|
Result: |
Delayed tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival. |
|
|
|
||
|
Animal Model: |
Male rats |
|
|
Dosage: |
30, 100mg/kg (Pharmacokinetic Analysis) |
|
|
Administration: |
Oral gavage twice a day; on days 1 and 5 |
|
|
Result: |
Had the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594ng/mL and AUC0-t in the plasma of 6950 and 13962ng.h/mL at 30 and 100mg/kg dosing, respectively. |
|
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
